JERUSALEM,
November 12, 2010
/PRNewswire-FirstCall/ --
Medisafe 1 Technologies
Corp. (OTCBB: MFTH), a
developer of patented
technologies that physically
prevent unauthorized
administration of
prescription medications,
announced today that the
company's exhibition of its
barcoded syringe
locking-device generated
significant interest at the
HealthAchieve Conference
November 8-10, in
Toronto, Canada.
Over 35 companies responded
favorably, including some of
the nation's largest medical
suppliers, expressing
interest in learning more
about the potential
widespread implementation of
the lifesaving device.
A report drawn up by a
third-party on Medisafe 1
Technologies' exhibit stated
the following, "The overall
response was overwhelmingly
favorable. The features and
benefits of the system were
immediately apparent and the
spontaneous response was
almost always that this is a
great product.
HealthAchieve is one of
the largest and most
prestigious health care
gatherings in
North America, with
over 9,000 health care and
business leaders from around
the world.
"We are very pleased with
the overwhelmingly positive
response our exhibition
received at the
HealthAchieve Conference,"
said,
Jacob Elhadad, CEO of
Medisafe 1 Technologies.
"This was the first such
presentation of our patented
syringe locking system.
Implementation of the system
in hospitals has the
potential to significantly
reduce the large number of
deaths that occur each year
due to improper
administration of
medicines."
About Medisafe 1
Technologies
Medisafe 1 Technologies
seeks to effectively prevent
unauthorized administration
of a drug or medicinal
substance by hypodermic
needle. Medisafe's patented
technology is a medical
assembly with a locking
mechanism that is intended
to ensure the substance
cannot be released from the
hypodermic needle without
positive pre-matching
between the substance and
its intended patient.
Forward-Looking
Statements
This letter contains
forward-looking statements
within the meaning of
Section 27A of the
Securities Act of 1933 as
amended and Section 21E of
the Securities Exchange Act
of 1934 as amended. All
forward-looking statements
are inherently uncertain,
based on current
expectations and assumptions
concerning future events or
future performance of
Medisafe 1 Technologies
Corp., and its technologies.
In evaluating such
statements, prospective
investors should review
carefully various risks and
uncertainties identified in
this release, as actual
results may differ
materially from those
indicated. Medisafe 1
Technologies Corp. public
filings may be viewed at
http://www.sec.gov.
Contact:
Jacob Elhadad
CEO
+972-524440000
Jacob.elhadad10@gmail.com
